Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | SLC26A4 | O43511 | 1/20 | 0.44 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.41 |
| ▸ | USP14 | P54578 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 2/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.37 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL503499 | 0.90 | MDM2 (0.45) | MEN1KMT2AUSP14PTGDRKDM4E | |
| SCHEMBL503414 | 0.88 | USP14 (0.42) | MEN1KMT2AUSP14PTGDRTP53 | |
| SCHEMBL503844 | 0.88 | MAOB (0.41) | MEN1KMT2AUSP14MAOBMAOA | |
| SCHEMBL503625 | 0.87 | USP14 (0.44) | MEN1KMT2ASLC26A4NR4A2USP14 | |
| SCHEMBL504142 | 0.87 | MEN1 (0.44) | MEN1KMT2ASLC26A4USP14MAOB | |
| SCHEMBL503554 | 0.86 | MEN1 (0.45) | MEN1KMT2ASLC26A4NR4A2USP14 | |
| SCHEMBL503872 | 0.86 | USP14 (0.48) | MEN1KMT2AUSP14PTGDRKDM4E | |
| SCHEMBL503599 | 0.85 | MAOB (0.40) | MEN1KMT2AUSP14MAOBPTGDR | |
| SCHEMBL503871 | 0.85 | MEN1 (0.48) | MEN1KMT2ATP53KDM4ENPC1 | |
| SCHEMBL503475 | 0.85 | KMT2A (0.43) | MEN1KMT2ATP53KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120029016-A1 | Indoles Useful in the Treatment of Inflammation | BIOLIPOX AB (SW) | 2012-02-02 | — | — | US | disclosed |
| US-20120029016-A1 | Indoles Useful in the Treatment of Inflammation | BIOLIPOX AB (SW) | 2012-02-02 | — | — | US | disclosed |
| US-20120029016-A1 | Indoles Useful in the Treatment of Inflammation | BIOLIPOX AB (SW) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120029016-A1 | Indoles Useful in the Treatment of Inflammation | LTC4S, LTB4R2, LTB4R | MEN1 2934/4885KMT2A 1783/4885SLC26A4 2206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.